Local iontophoretic administration of cytotoxic therapies to solid tumors

Science Translational Medicine

Volumn 7, Issue 273, 2015, Pages 273ra14-

  Byrne, James D ^a,b   Jajja, Mohammad R N ^c   O'Neill, Adrian T ^c   Bickford, Lissett R ^c   Keeler, Amanda W ^a   Hyder, Nabeel ^b   Wagner, Kyle ^b   Deal, Allison ^d   Little, Ryan E ^b   Moffitt, Richard A ^c   Stack, Colleen ^c,e,f   Nelson, Meredith ^c   Brooks, Christopher R ^g   Lee, William ^g   Luft, J Chris ^a,c   Napier, Mary E ^c   Darr, David ^c   Anders, Carey K ^b,c   Stack, Richard ^c,e,f   Tepper, Joel E ^b,c   Wang, Andrew Z ^b,c   Zamboni, William C ^a,c   Yeh, Jen Jen ^b,c   DeSimone, Joseph M ^a,b,c,g,h   more..

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Synecor LLC   (United States)

^g University of North Carolina at Chapel Hill   (United States)

^h North Carolina State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; GEMCITABINE; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANINE MODEL; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG TOXICITY; HUMAN; HUMAN TISSUE; IONTOPHORETIC DELIVERY DEVICE; LOCAL THERAPY; MOUSE; MOUSE MODEL; NONHUMAN; PANCREAS CANCER; SOLID TUMOR; SURVIVAL TIME; SYSTEMIC THERAPY; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL DEATH; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; EQUIPMENT DESIGN; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; IONTOPHORESIS; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; SKIN; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DOGS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; IONTOPHORESIS; MICE, INBRED BALB C; NEOPLASMS; SKIN; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84996561667     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009951     Document Type: Article

References (46)

1. L. S. Goodman, M. M. Wintrobe, W. Dameshek, M. J. Goodman, M. A. Gilman, M. T. McLennan, Nitrogen mustard therapy; use of methyl-bis (β-chloroethyl) amine hydrochloride and tris (β-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J. Am. Med. Assoc. 132, 126-132 (1946).
2. J. P. Neoptolemos, D. D. Stocken, H. Friess, C. Bassi, J. A. Dunn, H. Hickey, H. Beger, L. Fernandez-Cruz, C. Dervenis, F. Lacaine, M. Falconi, P. Pederzoli, A. Pap, D. Spooner, D. J. Kerr, M. W. Büchler; European Study Group for Pancreatic Cancer, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200-1210 (2004).
3. R. Sauer, H. Becker, W. Hohenberger, C. Rödel, C.Wittekind, R. Fietkau, P. Martus, J. Tschmelitsch, E. Hager, C. F. Hess, J. H. Karstens, T. Liersch, H. Schmidberger, R. Raab; German Rectal Cancer Study Group, Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731-1740 (2004).
4. D. Cunningham, W. H. Allum, S. P. Stenning, J. N. Thompson, C. J. Van de Velde, M. Nicolson, J. H. Scarffe, F. J. Lofts, S. J. Falk, T. J. Iveson, D. B. Smith, R. E. Langley, M. Verma, S. Weeden, Y. J. Chua; MAGIC Trial Participants, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11-20 (2006).
5. D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A. R. Norman; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom, Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36-46 (2008).
6. M. Hidalgo, Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617 (2010).
7. M. A. Clark, C. Fisher, I. Judson, J. M. Thomas, Soft-tissue sarcomas in adults. N. Engl. J. Med. 353, 701-711 (2005).
8. J. K. Tunggal, D. S. M. Cowan, H. Shaikh, I. F. Tannock, Penetration of anticancer drugs through solid tissue: A factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer Res. 5, 1583-1586 (1999).
9. K. P. Olive, M. A. Jacobetz, C. J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M. A. Goldgraben, M. E. Caldwell, D. Allard, K. K. Frese, G. Denicola, C. Feig, C. Combs, S. P. Winter, H. Ireland-Zecchini, S. Reichelt, W. J. Howat, A. Chang, M. Dhara, L. Wang, F. Rückert, R. Grützmann, C. Pilarsky, K. Izeradjene, S. R. Hingorani, P. Huang, S. E. Davies, W. Plunkett, M. Egorin, R. H. Hruban, N. Whitebread, K. McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, D. A. Tuveson, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
10. A. I. Minchinton, I. F. Tannock, Drug penetration in solid tumors. Nat. Rev. Cancer 6, 583-592 (2006).
11. I. F. Tannock, C. M. Lee, J. K. Tunggal, D. S. Cowan, M. J. Egorin, Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. 8, 878-884 (2002).
12. J. B. Wolinsky, Y. L. Colson, M. W. Grinstaff, Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafer. J. Control. Release 159, 14-26 (2012).
13. L. K. Fung, M. G. Ewend, A. Sills, E. P. Sipos, R. Thompson, M. Watts, O. M. Colvin, H. Brem, W. M. Saltzman, Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 58, 672-684 (1998).
14. Y. N. Kalia, A. Naik, J. Garrison, R. H. Guy, Iontophoretic drug delivery. Adv. Drug Deliv. Rev. 56, 619-658 (2004).
15. V. Merino, A. López, Y. N. Kalia, R. H. Guy, Electrorepulsion versus electroosmosis: Effect of pH on the iontophoretic flux of 5-fluorouracil. Pharm. Res. 16, 758-761 (1999).
16. S. M. Di Stasi, M. Valenti, C. Verri, E. Liberati, A. Giurioli, G. Leprini, F. Masedu, A. R. Ricci, F. Micali, G. Vespasiani, Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: A randomised controlled trial. Lancet Oncol. 12, 871-879 (2011).
17. A. E. Cohen, C. Assang, M. A. Patane, S. From, M. Korenfeld; Avion Study Investigators, Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating non-infectious anterior uveitis. Ophthalmology 119, 66-73 (2012).
18. R. J. Torphy, C. J. Tignanelli, J. W. Kamande, R. A. Moffitt, S. G. Herrera Loeza, S. A. Soper, J. J. Yeh, Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. PLOS One 9, e89474 (2014).
19. N. F. Neel, J. K. Stratford, V. Shinde, J. A. Ecsedy, T. D. Martin, C. J. Der, J. J. Yeh, Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. Mol. Cancer Ther. 13, 122-133 (2014).
20. J. Usary, W. Zhao, D. Darr, P. J. Roberts, M. Liu, L. Balletta, O. Karginova, J. Jordan, A. Combest, A. Bridges, A. Prat, M. C. U. Cheang, J. I. Herschkowitz, J. M. Rosen, W. Zamboni, N. E. Sharpless, C. M. Perou, Predicting drug responsiveness in human cancers using genetically engineered mice. Clin. Cancer Res. 19, 4889-4899 (2013).
21. D. Zhang, T. A. LaFortune, S. Krishnamurthy, F. J. Esteva, M. Cristofanilli, P. Liu, A. Lucci, B. Singh, M. C. Hung, G. N. Hortobagyi, N. T. Ueno, Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin. Cancer Res. 15, 6639-6648 (2009).
22. D. Li, K. Xie, R. Wolff, J. L. Abbruzzese, Pancreatic cancer. Lancet 363, 1049-1057 (2004).
23. R. L. Smoot, C. A. Koch, A. C. Degnim, S. Sterioff, J. H. Donohue, C. S. Grant, S. A. Barnes, R. E. Gullerud, T. J. Hobday, D. R. Farley, A single-center experience with inflammatory breast cancer, 1985-2003. Arch. Surg. 141, 567-572 (2006).
24. I. Fichtner, J. Rolff, R. Soong, J. Hoffmann, S. Hammer, A. Sommer, M. Becker, J. Merk, Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 14, 6456-6468 (2008).
25. A. C. Kimmelman, A. F. Hezel, A. J. Aguirre, H. Zheng, J. H. Paik, H. Ying, G. C. Chu, J. X. Zhang, E. Sahin, G. Yeo, A. Ponugoti, R. Nabioullin, S. Deroo, S. Yang, X.Wang, J. P. McGrath, M. Protopopova, E. Ivanova, J. Zhang, B. Feng, M. S. Tsao, M. Redston, A. Protopopov, Y. Xiao, P. A. Futreal, W. C. Hahn, D. S. Klimstra, L. Chin, R. A. DePinho, Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc. Natl. Acad. Sci. U.S.A. 105, 19372-19377 (2008).
26. B. Rubio-Viqueira, A. Jimeno, G. Cusatis, X. Zhang, C. Iacobuzio-Donahue, C. Karikari, C. Shi, K. Danenberg, P. V. Danenberg, H. Kuramochi, K. Tanaka, S. Singh, H. Salimi-Moosavi, N. Bouraoud, M. L. Amador, S. Altiok, P. Kulesza, C. Yeo, W. Messersmith, J. Eshleman, R. H. Hruban, A. Maitra, M. Hidalgo, An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12, 4652-4661 (2006).
27. J. J. Tentler, A. C. Tan, C. D. Weekes, A. Jimeno, S. Leong, T. M. Pitts, J. J. Arcaroli, W. A. Messersmith, S. G. Eckhardt, Patient-derived tumor xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338-350 (2012).
28. M. Singh, A. Lima, R. Molina, P. Hamilton, A. C. Clermont, V. Devasthali, J. D. Thompson, J. H. Cheng, H. Bou Reslan, C. C. Ho, T. C. Cao, C. V. Lee, M. A. Nannini, G. Fuh, R. A. Carano, H. Koeppen, R. X. Yu, W. F. Forrest, G. D. Plowman, L. Johnson, Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 28, 585-593 (2010).
29. H. Wang, M. Li, J. J. Rinehart, R. Zhang, Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: In vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin. Cancer Res. 10, 1633-1644 (2004).
30. M. Morfouace, A. Shelat, M. Jacus, B. B. Freeman III, D. Turner, S. Robinson, F. Zindy, Y. D. Wang, D. Finkelstein, O. Ayrault, L. Bihannic, S. Puget, X. N. Li, J. M. Olson, G. W. Robinson, R. K. Guy, C. F. Stewart, A. Gajjar, M. F. Roussel, Pemetrexed and gemcitabine as combination therapy for the treatment of group3 medulloblastoma. Cancer Cell 25, 516-529 (2014).
31. M. Komuro, K. Suzuki, M. Kanebako, T. Kawahara, T. Otoi, K. Kitazato, T. Inagi, K. Makino, M. Toi, H. Terada, Novel iontophoretic administration method for local therapy of breast cancer. J. Control. Release 168, 298-306 (2013).
32. B. K. Chang, T. H. Guthrie Jr., K. Hayakawa, L. P. Gangarosa Sr., A pilot study of iontophoretic cisplatin chemotherapy of basal and squamous cell carcinomas of the skin. Arch. Dermatol. 129, 425-427 (1993).
33. M. L. Welch, W. J. Grabski, M. L. McCollough, H. G. Skelton, K. J. Smith, P. A. Menon, L. L. Anderson, 5-Fluorouracil iontophoretic therapy for Bowen's disease. J. Am. Acad. Dermatol. 36, 956-958 (1997).
34. T. Gratieri, Y. N. Kalia, Targeted local simultaneous iontophoresis of chemotherapies for topical therapy of head and neck cancers. Int. J. Pharm. 460, 24-27 (2014).
35. C. R. Ferrone, M. F. Brennan, M. Gonen, D. G. Coit, Y. Fong, S. Chung, L. Tang, D. Klimstra, P. J. Allen, Pancreatic adenocarcinoma: The actual 5-year survivors. J. Gastrointest. Surg. 12, 701-706 (2008).
36. S. Gillen, T. Schuster, C. Meyer Zum Büschenfelde, H. Friess, J. Kleeff, Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLOS Med. 7, e1000267 (2010).
37. M. F. Berry, Esophageal cancer: Staging system and guidelines for staging and treatment. J. Thorac. Dis. 6, S289-S297 (2014).
38. S. Lin, K. Hoffmann, P. Schemmer, Treatment of hepatocellular carcinoma: A systematic review. Liver Cancer 1, 144-158 (2012).
39. C. Laroche, F. Wells, R. Coulden, S. Stewart, M. Goddard, E. Lowry, A. Price, D. Gilligan, Improving surgical resection rate in lung cancer. Thorax 53, 445-449 (1998).
40. S. Msika, M. A. Tazi, A. M. Benhamiche, C. Couillault, M. Harb, J. Faivre, Population-based study of diagnosis, treatment and prognosis of gastric cancer. Br. J. Surg. 84, 1474-1478 (1997).
41. H. Suit, S. Goldberg, A. Niemierko, M. Ancukiewicz, E. Hall, M. Goitein, W. Wong, H. Paganetti, Secondary carcinogenesis in patients treated with radiation: A review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat. Res. 167, 12-42 (2007).
42. T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J. L. Raoul, S. Gourgou-Bourgade, C. de la Fouchardière, J. Bennouna, J. B. Bachet, F. Khemissa-Akouz, D. Péré-Vergé, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, M. Ducreux; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825 (2011).
43. A. E. Rose, K. J. Azevedo, C. K. Payne, Office bladder distention with Electromotive Drug Administration (EMDA) is equivalent to distention under General Anesthesia (GA). BMC Urol. 5, 14 (2005).
44. N. Kemeny, J. Daly, B. Reichman, N. Geller, J. Botet, P. Oderman, Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann. Intern. Med. 107, 459-465 (1987).
45. M. N. Kirstein, I. Hassan, D. E. Guire, D. R. Weller, J. W. Dagit, J. E. Fisher, R. P. Remmel, High performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 835, 136-142 (2006).
46. W. P. Caron, J. C. Lay, A. M. Fong, N. M. La-Beck, P. Kumar, S. E. Newman, H. Zhou, J. H. Monaco, D. L. Clarke-Pearson, W. R. Brewster, L. Van Le, V. L. Bae-Jump, P. A. Gehrig, W. C. Zamboni, Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. J. Pharmacol. Exp. Ther. 347, 599-606 (2013).